Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06625593 | A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 168 | BeOne MedicinesINDUSTRY | 4 | Jul 9, 2026 | clinicaltrials |
| NCT06651593 | Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06874335 | A Phase 1 Study of BHV-1530 in Advanced Solid Tumors | recruiting | Phase 1 | 140 | Biohaven Therapeutics Ltd.INDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07691775 | A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | Heron Neutron Medical Corp.INDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04116541 | A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.(MegaMOST) | recruiting | Phase 2 | 455 | Centre Leon BerardOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06200116 | Evaluation of a Novel Auto Segmentation Algorithm for Normal Structure Delineation in Radiation Treatment Planning | recruiting | — | 200 | Mayo ClinicOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06320405 | Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 38 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06888830 | A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour | recruiting | Phase 1 / Phase 2 | 374 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06989489 | Implementation of an Oral Chemotherapy Adherence Intervention | recruiting | N/A | 160 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05768139 | First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors(PIKALO-1) | recruiting | Phase 1 / Phase 2 | 880 | Eli Lilly and CompanyINDUSTRY | 9 | Jul 7, 2026 | clinicaltrials |
| NCT06824363 | ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu | recruiting | Early Phase 1 | 34 | University of California, IrvineOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07325006 | Impact of Physician Behavior on Cancer Distress | recruiting | — | 5,000 | Mayo ClinicOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07337525 | A First in Human Study of PLT012 in Participants With Solid Tumor Cancers | recruiting | Phase 1 | 36 | Pilatus Biosciences IncINDUSTRY | 1 | Jul 7, 2026 | clinicaltrials |
| NCT02332668 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | recruiting | Phase 1 / Phase 2 | 370 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT06043713 | Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations | recruiting | Phase 1 | 24 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07300150 | A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors | recruiting | Phase 1 | 210 | PAQ Therapeutics, Inc.INDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT04942717 | Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values | recruiting | N/A | 234 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05943119 | Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surgery(SinocaRT) | recruiting | Phase 2 | 52 | Centre Francois BaclesseOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05722886 | DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol(DETERMINE) | recruiting | Phase 2 / Phase 3 | 825 | Cancer Research UKOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07664150 | CW-301 FIH Study of CAN016 | recruiting | Phase 1 / Phase 2 | 90 | Canwell Biotech LimitedINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05170958 | A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors | recruiting | Phase 1 / Phase 2 | 396 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05301101 | High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis(REDIRICT) | recruiting | N/A | 120 | Medical College of WisconsinOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05720117 | A Study of PYX-201 in Advanced Solid Tumors | recruiting | Phase 1 | 330 | Pyxis Oncology, IncINDUSTRY | 4 | Jun 30, 2026 | clinicaltrials |
| NCT06897137 | Optimizing Health Related Quality of Life Measurement in Adolescent and Young Adult Oncology | recruiting | — | 3,000 | Wake Forest University Health SciencesOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07675967 | Clonal Hematopoiesis Chemotherapy and Radiation Effects Study(CH CARE) | recruiting | — | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT01137825 | Registry of Older Patients With Cancer | recruiting | — | 3,000 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07140393 | A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor | recruiting | Phase 1 / Phase 2 | 120 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07508761 | IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 52 | Nanjing Immunophage Biotech Co., LtdINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05861895 | HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors | recruiting | Phase 1 | 84 | HighField Biopharmaceuticals CorporationINDUSTRY | 2 | Jun 26, 2026 | clinicaltrials |
| NCT07606612 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 31 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04219254 | A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 197 | BioInvent International ABINDUSTRY | 7 | Jun 25, 2026 | clinicaltrials |
| NCT06220864 | SNV1521 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 400 | Synnovation Therapeutics, Inc.INDUSTRY | 7 | Jun 25, 2026 | clinicaltrials |
| NCT06352359 | Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors | recruiting | Phase 1 | 72 | OncoC4, Inc.INDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06431594 | A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1) | recruiting | Phase 1 | 675 | GlaxoSmithKlineINDUSTRY | 15 | Jun 25, 2026 | clinicaltrials |
| NCT07365007 | A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors Post-treatment | recruiting | N/A | 50 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06952010 | A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 303 | ExelixisINDUSTRY | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07060989 | A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation(NTS071) | recruiting | Phase 1 / Phase 2 | 220 | Nutshell Therapeutics (Shanghai) Co., LTD.INDUSTRY | 2 | Jun 24, 2026 | clinicaltrials |
| NCT07664579 | Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer | recruiting | — | 160 | City of Hope Medical CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04678648 | A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies | recruiting | Phase 1 | 134 | RasCal Therapeutics, Inc.INDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05584670 | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | SanofiINDUSTRY | 6 | Jun 23, 2026 | clinicaltrials |
| NCT05684965 | XTX301 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 358 | Xilio Development, Inc.INDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06640010 | Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events | recruiting | — | 30 | Mayo ClinicOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06993844 | Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 233 | Ensem TherapeuticsINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT07291011 | A Mindfulness-Based Stress Reduction Program for Improving Mental Health Outcomes for Underserved Cancer Patients in Minnesota | recruiting | N/A | 45 | Mayo ClinicOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05434234 | A Study of YL201 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 312 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 6 | Jun 22, 2026 | clinicaltrials |
| NCT07216534 | Virtual Reality Viewing of Unaltered Streetscape Versus Digitally Manipulated Opposite Streetscape to Assess Psychosocial Response in Participants | recruiting | N/A | 32 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05694715 | Combination Therapy in Cancers With Mutations in DNA Repair Genes | recruiting | Phase 1 | 24 | University of California, San FranciscoOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06075524 | Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types | recruiting | — | 500 | Mayo ClinicOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06579469 | Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy | recruiting | — | 100 | St. Jude Children's Research HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 9, 2026source: clinicaltrials